The UK and US have secured a landmark trade agreement that will keep no import taxes on British medicine exports entering the US market.
The Terms of the Deal
Under the terms of the agreement, the UK has agreed to boost spending on medicines through the National Health Service (NHS). This commitment guarantees that duties on these key exports will remain at nothing for a period of 36 months.
This deal is in response to recent threats to dramatically increase tariffs on branded drug products, with figures floated reaching one hundred percent.
"This agreement between the Britain reinforces the global environment for innovative medicines and establishes long-overdue equity to U.S.–U.K. pharmaceutical trade," a statement said.
Trade Significance
Medicines constitute one of the Britain's largest exports to the US, which is by far the biggest market for large UK drugmakers.
Trade data show that in the year leading up to last September, the UK sold medicines totaling £11.1bn to the US. This figure accounted for 17.4% of British export trade in that timeframe.
"This agreement protects employment, stimulates capital expenditure and sets the stage for the UK to become a international leader for biotech and pharma," a government official stated.
Key UK Commitments
The agreement entails several key pledges from the British government:
- Revised Affordability Limit: The UK will raise the price threshold at which it judges new treatments to be too expensive by a quarter.
- Boosted Medicine Funding: There is a target to raise overall health service expenditure on medicines from 0.3 percent of GDP to 0.6% over the coming ten years.
- Refund Ceiling: The percentage manufacturers must pay back to the NHS to stay within budget will be capped at fifteen percent. Previously, rebates exceeded twenty percent.
Industry Background
The pact takes place against a long-running row between the pharmaceutical industry and the UK government over drug pricing and approval rates.
These tensions were intensified by arguments that American patients were charged significantly more for the identical medicines than consumers in the UK and Europe.
In recent months, several large pharmaceutical investments in the UK have been halted or cancelled, while substantial funding commitments have been pledged toward projects in the United States.
A senior figure acknowledged that the NHS had to spend more on drugs, noting that its spending on drugs had decreased as a share of its resources over the past decade.
